Myriad Genetics to Announce Third Quarter 2024 Results
Myriad Genetics, Inc. (NASDAQ: MYGN), known for its role in genetic testing and precision medicine, is poised to release its financial results for the third quarter of 2024. The announcement is expected on November 7, 2024, after the market closes. Following the earnings release, the company will host a conference call at 4:30 PM ET that same day. During the call, executives at Myriad will provide a comprehensive overview of the company’s financial performance and insights into ongoing business initiatives.
How to Access the Earnings Call
For those interested in participating, a live webcast of the earnings conference call will be available through Myriad's Investor Relations website. Furthermore, investors wishing to join the call by phone can do so by registering in advance. This process will ensure they receive a unique dial-in number and PIN for access. After the event, an archived version of the webcast will also be accessible online, allowing stakeholders to review the presentation and discussions at their convenience.
Upcoming Investor Conference Participation
In addition to the earnings call, management at Myriad Genetics will be active in several notable investor healthcare conferences throughout the month. At the Guggenheim Inaugural Global Healthcare Conference, Paul J. Diaz, President and CEO, will engage in a fireside chat scheduled for November 13, 2024, at 3:30 PM ET. Following that, Scott Leffler, Chief Financial Officer, and Sam Raha, Chief Operating Officer, will represent Myriad at the 6th Annual Wolfe Research Healthcare Conference on November 20, 2024, at 3:20 PM ET.
Webcasts Available for All Conference Presentations
Investors and interested parties will be able to view the live and archived webcasts for all presentations at Myriad's Investor Relations website. This opportunity allows stakeholders to gain invaluable insights into the company's strategies and expert opinions from executive leadership during these significant industry events.
About Myriad Genetics
Myriad Genetics stands as a leading force in genetic testing and precision medicine, dedicated to enhancing health and well-being. The company specializes in developing innovative genetic tests, designed to evaluate the risk of disease development and progression. Myriad's solutions guide essential treatment decisions across various medical specialties and have been shown to improve patient care while reducing healthcare costs significantly. By focusing on genetic insights, Myriad strives to provide a more personalized approach to healthcare.
Contact Information for Investors
Investors seeking more information about Myriad Genetics' performance, upcoming events, or corporate strategy can contact:
Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com
Media Contact
Glenn Farrell
(385) 318-3718
PR@myriad.com
Frequently Asked Questions
When will Myriad Genetics release its third quarter 2024 results?
Myriad Genetics will announce its Q3 2024 financial results on November 7, 2024, after the market closes.
How can I participate in the earnings conference call?
To join the earnings conference call, you need to register in advance to receive a unique dial-in number and PIN.
Who will represent Myriad Genetics at the upcoming investor conferences?
Paul J. Diaz, Scott Leffler, and Sam Raha will represent Myriad Genetics at various healthcare investor conferences throughout the month.
Where can I find the archived webcasts of the presentations?
The archived webcasts of Myriad's presentations will be available on its Investor Relations website after the events.
What does Myriad Genetics do?
Myriad Genetics specializes in genetic testing and precision medicine, focusing on developing tests that assess disease risk and guide treatment decisions for better patient care.